Passage Historical Income Statement
| PASG Stock | USD 0.62 0.11 21.57% |
Historical analysis of Passage Bio income statement accounts such as Selling General Administrative of 34.6 M, Total Revenue of 0.0, Other Operating Expenses of 106.4 M or Research Development of 70.7 M can show how well Passage Bio performed in making a profits. Evaluating Passage Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Passage Bio's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Passage Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Passage Bio is a good buy for the upcoming year.
Passage |
About Passage Income Statement Analysis
Passage Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Passage Bio shareholders. The income statement also shows Passage investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Passage Bio Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Passage Bio. It is also known as Passage Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Passage Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Passage Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.At this time, Passage Bio's Research Development is most likely to increase significantly in the upcoming years. The Passage Bio's current Reconciled Depreciation is estimated to increase to about 4.1 M, while Interest Expense is projected to decrease to roughly 2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 343K | 2.3M | 2.0M | 2.0M | Depreciation And Amortization | 1.5M | 3.7M | 3.7M | 2.8M |
Passage Bio income statement Correlations
Click cells to compare fundamentals
Passage Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Passage Bio income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 696K | 670K | 343K | 2.3M | 2.6M | 2.7M | |
| Interest Income | 696K | 670K | 343K | 2.3M | 2.6M | 2.7M | |
| Depreciation And Amortization | 10.3M | 800K | 1.5M | 3.7M | 3.7M | 2.8M | |
| Interest Expense | 8.4M | 670K | 343K | 2.3M | 2.0M | 2.0M | |
| Selling General Administrative | 7.0M | 30.1M | 60.1M | 49.3M | 41.6M | 34.6M | |
| Other Operating Expenses | 36.7M | 111.9M | 177.7M | 135.4M | 108.4M | 106.4M | |
| Operating Income | (37.2M) | (112.9M) | (185.7M) | (138.4M) | (108.4M) | (113.8M) | |
| Net Income From Continuing Ops | (45.6M) | (112.2M) | (185.8M) | (136.7M) | (112.4M) | (118.0M) | |
| Ebit | (37.2M) | (113.7M) | (187.3M) | (142.1M) | (102.1M) | (107.2M) | |
| Research Development | 29.7M | 81.8M | 117.7M | 86.1M | 61.4M | 70.7M | |
| Ebitda | (26.9M) | (112.9M) | (185.7M) | (138.4M) | (98.3M) | (103.3M) | |
| Total Operating Expenses | 36.7M | 111.9M | 177.7M | 135.4M | 108.4M | 106.4M | |
| Reconciled Depreciation | 134K | 800K | 1.5M | 3.7M | 3.9M | 4.1M | |
| Income Before Tax | (45.6M) | (112.2M) | (185.4M) | (136.1M) | (102.1M) | (107.2M) | |
| Total Other Income Expense Net | (8.4M) | 670K | 343K | 2.3M | 6.3M | 6.6M | |
| Net Income Applicable To Common Shares | (45.6M) | (112.2M) | (185.4M) | (136.1M) | (122.5M) | (128.6M) | |
| Net Income | (54.6M) | (111.8M) | (191.5M) | (136.9M) | (102.1M) | (107.2M) | |
| Income Tax Expense | 8.9M | (470K) | 6.1M | 731K | 5.4M | 3.7M |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.